CHICAGO and FORT WORTH, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...

The MarketWatch News Department was not involved in the creation of this content. -- Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney ...

Positive full results from the Phase III TULIP-SC trial showed the subcutaneous administration of Saphnelo demonstrated a statistically ...

Change from baseline at day 56 (week eight) in tear production (Schirmer’s test). Change from baseline at day 56 in ocular symptoms measured by OSDI score. The study also met secondary endpoints, ...

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (ROIV) today announced positive results from the induction period of the TUSCANY-2 Phase 2b ...

DM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic Blood Pressure for Combined Cohorts 6-9 DM199 Did Not Cross the Placental Barrier and ...

Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving ...

Princess U. Ogbogu, Division Chief of Pediatric Allergy, Immunology, and Rheumatology at University Hospitals Rainbow Babies and Children’s Hospital and Case Western Reserve University, Cleveland, OH, ...

Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and ...

SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late ...